| Filed On | Filing |
|---|---|
| 01 Jun 2026 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| 01 Jun 2026 | TOTAL VOTING RIGHTS |
| 29 May 2026 | IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER |
| 28 May 2026 | 25-NSE |
| 27 May 2026 | US FDA DECISION DATE ON CAMIZESTRANT EXTENDED |
| 26 May 2026 | ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS |
| 26 May 2026 | DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC |
| 26 May 2026 | CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU |
| 22 May 2026 | OWNERSHIP DOCUMENT |
| 18 May 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 18 May 2026 | BAXFENDY APPROVED IN THE US FOR HYPERTENSION |
| 18 May 2026 | ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS |
| 14 May 2026 | IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER |
| 08 May 2026 | OWNERSHIP DOCUMENT |
| 01 May 2026 | FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER |
| 01 May 2026 | TOTAL VOTING RIGHTS AND ADMISSION OF SHARES |
| 01 May 2026 | FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER |
| 29 Apr 2026 | 1ST QUARTER RESULTS |
| 28 Apr 2026 | SCHEDULE 13G |
| 28 Apr 2026 | BREZTRI APPROVED IN THE US FOR ASTHMA |
Loading...
